Drug news
GSK ends work on GSK 2586184 for treatment of Psoriasis and Ulcerative Colitis
Reuters reports that GSK has decided to end work on its drug GSK 2586184 for treatment of Ulcerative Colitis and Psoriasis which it is developing with Galapagos, after tests showed it did not combine well with certain cholesterol drugs. Galapagos said that it could not comment on GSK's study because it had not seen the full results of the test. GSK said it was considering how to proceed with the project.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.